** Shares of Cleo Diagnostics COV.AX rise as much as 17.7% to A$0.400, their highest level since May 5
** Stock set for its best day since April 14, if trends sustain
** The cancer diagnostics tests provider receives approval from U.S. National Cancer Institute to access blood samples from the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial
** Around 209,750 shares change hands, busiest day since May 19
** Stock up 4.2%, YTD
(Reporting by Keshav Singh Chundawat in Bengaluru)
((Keshav.SinghChundawat@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。